Diabetic peripheral neuropathy (DPN) is one of the most commonly occurring major complications of diabetes. The disease may manifest in several clinical patterns: most frequently as distal symmetrical sensory polyneuropathy. Guidelines are available for the diagnosis of DPN by the primary care physician. These recommend that a review of diabetic patients, including a questionnaire and inspection and neurological examination of the feet, is undertaken annually. Techniques used for studying the disease process in clinical trials may include nerve conduction and quantitative sensory function tests, autonomic nervous system testing, post-ganglionic sudomotor function and skin biopsy. Current therapies for managing DPN are strict glycaemic control, palliative treatments and foot ulcer prevention. Future treatments aim to beneficially affect the underlying disease pathology and putative agents are currently being investigated.

Keywords:
Diabetic peripheral neuropathy, Disease progression, Disease management, Diagnostic tests, Clinical trials, tools, Diabetes mellitus, Palliative care, Foot ulcer
1.
Thomas PK: Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes 1997;46(suppl 2):54–57.
2.
Said G: Diabetic neuropathy: An update. J Neurol 1996;243:431–440.
3.
Andersen H, Jakobsen J: Diabetes mellitus. Curr Opin Neurol 1997;10:376–380.
4.
Dyck PJ, Kratz KM, Karnes JL, Litchy WJ, Klein R, Pach JM, Wilson DM, O’Brien PC, Melton LJ III, Service FJ: The prevalence by staged severity of various types of diabetic neuropathy, retinopathy in a population-based cohort: The Rochester Diabetic Neuropathy Study. Neurology 1993;43:817–824, erratum p 2345.
5.
Tesfaye S, Stevens LK, Stephenson JM, Fuller JH, Plater M, Ionescu-Tirgoviste C, Nuber A, Pozza G, Ward JD, and the EURODIAB IDDM Study Group: Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: The EURODIAB IDDM Complications Study. Diabetologia 1996;39:1377–1384.
6.
Stephenson JM, Kempler P, Cavallo Perin P, Fuller JH, and the EURODIAB IDDM Complications Study: Is autonomic neuropathy a risk factor for severe hypoglycemia? The EURODIAB IDDM Complications Study. Diabetologia 1996;39:1372–1376.
7.
Harris M, Eastman R, Cowie C: Symptoms of sensory neuropathy in adults with NIDDM in the US population. Diabetes Care 1993;16:1446–1452.
8.
Pirart J: Diabetes mellitus and its degenerative complications: A prospective study of 4,400 patients observed between 1947 and 1973. Diabetes Care 1978;1:168–188, 252–263.
9.
Thomas PK, Tomlinson DR: Diabetic and hypoglycemic neuropathy; in Dyck PJ, Thomas PK (eds): Peripheral Neuropathy. Philadelphia, Saunders, 1993, pp 1219–1250.
10.
Boulton AJM, Jervell JA: Guidelines for the diagnosis and out-patient management of DPN. Diabetic Med 1998;15:508–514.
11.
Garland H, Taverner D: Diabetic myelopathy. Br Med J 1953;i:1405–1408.
12.
Orskov L, Worm M, Schmitz O, Mengel A, Sidenius P: Nerve conduction velocity in man: Influence of glucose, somatostatin and electrolytes. Diabetologia 1994;37:1216–1220.
13.
Albers JW, Brown MB, Sima AA, Greene DA: Nerve conduction measures in mild diabetic neuropathy in the Early Diabetes Intervention Trial: The effects of age, sex, type of diabetes, disease duration, and anthropometric factors. Tolrestat Study Group for the Early Diabetes Intervention Trial. Neurology 1996;46:85–91.
14.
Dyck PJ, Arezzo JC, Bolton CF, Casey KL, Cornblath D, Fields HL, Hanson P, Greenspan J, Harati Y, Jamal GA, Kennedy WR, Kenshalo DR, Light AR, Lindblom U, O’Brien P, Ochoa J, Zimmerman I: Quantitative sensory testing: A consensus report from the Peripheral Neuropathy Association. Neurology 1993;43:1050–1052.
15.
Guy RJC, Clark CA, Malcolm PM, Watkins PJ: Evaluation of thermal and vibration sensation in diabetic neuropathy. Diabetologia 1985;28:131–137.
16.
Ravits JM: AAEM mini monograph #48: Autonomic nervous system testing. Muscle Nerve 1997;20:919–937.
17.
Kennedy WR, Navarro X: Sympathetic sudomotor function in diabetic neuropathy. Arch Neurol 1989;46:1182–1186.
18.
Kennedy WR, Wendelschafer-Crabb G: Utility of skin biopsy in diabetic neuropathy. Semin Neurol 1996;16:163–171.
19.
Stevens MJ, Feldman EL, Greene DA: The aetiology of diabetic neuropathy: The combined roles of metabolic and vascular defects. Diabetic Med 1995;12:566–579.
20.
Diabetes Control and Complications Trial Research Group: The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561–568.
21.
Said G, Elgrably F, Lacroix C, Plante V, Talamon C, Adams D, Tager M, Slama G: Painful proximal diabetic neuropathy: Inflammatory nerve lesions and spontaneous favorable outcome. Ann Neurol 1997;41:762–770.
22.
Diabetic Control and Complications Trial Research Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–986.
23.
Kennedy WR, Navarro X, Goetz FC, Sutherland DE, Najarian JS: Effects of pancreatic transplantation on diabetic neuropathy. N Engl J Med 1990;322:1031–1037.
24.
Nicolucci A, Carinci F, Graepel JG, Hohman TC, Ferris F, Lachin JM: The efficacy of tolrestat in the treatment of diabetic peripheral neuropathy: A meta-analysis of individual patient data. Diabetes Care 1996;19:1091–1096.
25.
Pfeifer MA, Schumer MP, Gelber DA: Aldose reductase inhibitors: The end of an era or the need for different trial designs? Diabetes 1997;46(suppl 2):82–89.
26.
Gamma-Linolenic Acid Multicenter Trial Group: Treatment of diabetic neuropathy with gamma-linolenic acid. Diabetes Care 1993;16:8–15.
27.
Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium- ATPase in the pathogenesis of diabetes complications. N Engl J Med 1987;316:599–606.
28.
Jamal GA, Carmichael H: The effect of gamma-linolenic acid on human diabetic polyneuropathy: A double-blind placebo-controlled trial. Diabetic Med 1990;7:319–323.
29.
Ziegler D, Hanefeld M, Ruhnau KJ, Meissner HP, Lobisch M, Schutte K, Gries FA: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid: A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995;38:1425–1433.
30.
Rodriguez-Pena A, Botana M, Gonzalez M, Requejo F: Expression of neurotrophins and their receptors in sciatic nerve of experimentally diabetic rats. Neurosci Lett 1995;200:37–40.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.